Gonadotropin-releasing hormone receptor expression in endometrial stromal sarcomas: an immunohistochemical study

Abstract

Gonadotropin-releasing hormone and its receptors have been identified in several human malignancies. We evaluated gonadotropin-releasing hormone receptor expression in 30 primary and recurrent endometrial stromal sarcomas. Archival formalin-fixed and paraffin-embedded material was analyzed immunohistochemically with antisera to gonadotropin-releasing hormone receptor type I and gonadotropin-releasing hormone receptor type II using the peroxidase-antiperoxidase method. Gonadotropin-releasing hormone receptor types I and II were demonstrated in most primary endometrial stromal sarcomas in varying intensity and percentage (range, 10-100%). The staining pattern was either diffuse cytoplasmic or granular/vesicular in perinuclear distribution. Recurrences stained stronger than primary tumors. The demonstration of gonadotropin-releasing hormone receptors I and II expression in endometrial stromal sarcomas may be a rationale for a clinical study of gonadotropin-releasing hormone analogs in the treatment of women with endometrial stromal sarcomas.

Intracellular gonadotropin-releasing hormone receptors in breast cancer and gonadotrope lineage cells

“…However, most of the earlier work was with rat and mouse GnRHRs, which lack the primate-specific K191 residue and have a second aminoterminal glycosylation site, features absent from the hGnRHR that favor plasma membrane expression. To our knowledge, the compartmentalization of human pituitary GnRHRs has not been defined in this way but subpopulations of intracellular GnRHRs have been reported in some models (Halmos & Schally 2002) and immunohistochemical approaches have revealed cytoplasmic hGnRHRs in tissues including breast carcinomas (Moriya et al 2001, Reich et al 2005. Such observations have remained controversial, largely because of the lack of reliable and well-characterized GnRHR antibodies, but are entirely compatible with our data that hGnRHRs are predominantly intracellular in MCF7 breast cancer cells.…”

Mixed epithelial and stromal tumour of the kidney with luteinised ovarian stroma

“…We report for the first time in MESTs the presence of luteinised ovarian-type cells, whose identity is supported by the positivity of highly specific immunohistochemical markers such as a-inhibin, calretinin, 10 aromatase and GnRH receptors. 11 Thus, we can conclude that this tissue is identical to ovarian stroma.…”

Prognostic factors and status of hormone receptors and angiogenic factors in uterine carcinosarcoma

“…For determination of immunoreactivity, two slides containing each sample were immunostained in separate runs, and the immunohistochemical analysis was performed by two examiners who were completely blinded to each patient's clinical information. We determined a case as 'positive' when more than 5% of tumor cells showed immunoreactivity for hormone receptors, 20 platelet-derived endothelial cell growth factor (PD-ECGF) 21 and vascular endothelial growth factor (VEGF), 22 more than 10% for gonadotropin-releasing hormone receptor (GnRHa) 4 and more than 25% for platelet-derived growth factor receptor-β (PDGFR). 9 We performed statistical analyses using χ 2 -tests, log-rank tests and Cox's proportional hazards models.…”

“…In the current study, we evaluated the expression of hormone receptors and angiogenic factors in the carcinomatous and sarcomatous components to identify appropriate selection of hormonal-based or moleculartargeted therapy. Furthermore, we studied the usefulness of hormone receptors, [3][4][5][6] angiogenic factors, [7][8][9][10][11] and biochemical characteristics, such as carbohydrate antigen (CA)-125, 12 preoperative hemoglobin level, 13,14 preoperative thrombocytosis, [13][14][15][16][17] and C-reactive protein (CRP) 18,19 as prognostic factors of endometrial cancer or uterine sarcoma.…”